Issuu

BIOPHARMACEUTICAL INDUSTRY

GLOBAL MEDICAL COMMUNICATIONS– GLOBAL MEDICAL AFFAIRS GLOBAL PATIENT SAFETY GLOBAL REGULATORY AFFAIRS GLOBAL VALUE, ACCESS & PRICING PRODUCT DEVELOPMENT AND CLINICAL SUPPLY US MARKET ACCESS US MEDICAL AFFAIRS US REVIEW AND STRATEGY

FELLOWSHIP PROGRAMS

ABOUT ALEXION

SERVING PATIENTS IN

COUNTRIES

30+

YEARS OF LEADERSHIP IN RARE DISEASE

APPROVED MEDICINES

RARE DISEASES

2025

CONTENTS

About Alexion, AstraZeneca Rare Disease

Fellowship Program Overview

10 Global Medical Communications–Global Medical Affairs 14

Global Patient Safety

Global Regulatory Affairs

Global Value, Access & Pricing

20 Product Development and Clinical Supply 22 US Market Access 24 US Medical Affairs 26 US Review and Strategy 30 Massachusetts College of Pharmacy and Health Sciences (MCPHS) 32 Application Requirements

HEADQUARTERS Alexion, AstraZeneca Rare Disease is headquartered in Boston, Massachusetts. Each fellowship program is two years in duration and most will be based in Boston.

ABOUT

ALEXION, ASTRAZENECA RARE DISEASE

Our mission is to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, as well as supportive technologies. At Alexion, AstraZeneca Rare Disease we invest in and value people who believe in the importance of our mission and understand what it takes to deliver on it. Our culture is rooted in integrity, inclusiveness and our dedication to joining and supporting the communities in which we live and work. Today, our internal research efforts focus on leveraging our 30+ years of leadership in rare disease. This knowledge allows us to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our development efforts focus on the core therapeutic areas of hematology, nephrology, rare cancers, neurology, endocrinology, bone metabolism and cardiology. We continue to lead in complement science by exploring new targets, and expand beyond complement to strengthen our clinical-stage pipeline through internal and external development opportunities in our core areas. Every day, people living with rare diseases, their caregivers and families face fears of the unknown with courage, tenacity and grace. We believe it is our responsibility to listen to, understand and change their lives.

Over the past year, I’ve had the opportunity to collaborate on several crossfunctional projects and help champion new solutions for our patients.” SAWYER PATRICK, PharmD, RPh

WE FOLLOW

WE PUT

WE PLAY

WE DO THE

WE ARE

THE SCIENCE

PATIENTS FIRST

TO WIN

RIGHT THING

ENTREPRENEURIAL

Our culture values are the guiding principles behind why and how we do our important work.

OUR

VALUES

The work we do is guided by people affected by rare diseases. We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives.

OUR

COMMITMENT TO INCLUSION & DIVERSITY We create a working environment that fosters continuous innovation, constant learning and propels our growth as individuals and for our company. That is why we aim to create an inclusive workplace and a workforce that reflects our communities and the patients we serve.

This includes equitable compensation, benefits and opportunities for development and advancement. We believe that inclusion is a right and diversity is a strength. Both make a fundamental contribution to the success of our company because innovation requires breakthrough ideas that only come from a diverse workforce empowered to challenge conventional thinking. We believe our shared creativity unlocks challenges and brings new solutions. Incorporating Inclusion and Diversity (I&D) across all aspects of our organization is imperative to innovating for patients, continuous learning and growing as individuals and as a company. Inclusion and diversity is one of the foundations of our People strategy — driving innovation, engagement and a sense of connection and belonging. We focus on four areas:

•

EMPOWERING inclusive leadership

•

FOSTERING an environment where we each speak our minds

•

BUILDING and sustaining a diverse leadership and talent pipeline

•

CONTRIBUTING to society, which includes our commitments to supplier diversity, clinical trial diversity and health equity

THERAPEUTIC AREAS Hematology Nephrology

VI CTOR LIVING WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Cardiology Neurology Endocrinology Bone Metabolism Rare Cancers

C H E LS EY LIVING WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

ARIA LIVING WITH HYPOPHOSPHATASIA

ALEXION/MCPHS

FELLOWSHIP PROGRAM

Alexion, in collaboration with Massachusetts College of Pharmacy and Health Sciences (MCPHS), is pleased to offer exceptional postdoctoral fellowship programs to candidates obtaining a Doctor of Pharmacy. Through this experience, fellows will gain exposure to the biopharmaceutical industry, enhancing their understanding and establishing a foundation as an industry professional.

GLOBAL MEDICAL COMMUNICATIONS– GLOBAL MEDICAL AFFAIRS 2 POSITIONS. BOSTON, MA

GLOBAL PATIENT SAFETY 1 POSITION. BOSTON, MA

GLOBAL REGULATORY AFFAIRS 1 POSITION. BOSTON, MA

GLOBAL VALUE, ACCESS & PRICING 1 POSITION. BOSTON, MA

PRODUCT DEVELOPMENT AND CLINICAL SUPPLY 1 POSITION. NEW HAVEN, CT

US MARKET ACCESS 1 POSITION. BOSTON, MA

US MEDICAL AFFAIRS 1 POSITION. BOSTON, MA

US REVIEW AND STRATEGY 1 POSITION. BOSTON, MA

Through strong mentorship, cross-functional collaboration, and the inspiring experience of contributing to a mission that improves the lives of patients with rare diseases, this fellowship has been truly career-shaping.” ZAHRA ARSALAN, PharmD, RPh

GLOBAL MEDICAL COMMUNICATIONS– GLOBAL MEDICAL AFFAIRS

2-YEAR PROGRAM MEDICAL INFORMATION 9 MONTHS

MEDICAL REVIEW 9 MONTHS

ELECTIVE 6 MONTHS

his two-year program offers fellows the opportunity to gain extensive experience within Global Medical Communications and Global Medical Affairs

in a fast-paced and patient-centric biopharmaceutical company focused on developing and delivering life-changing therapies for patients with rare diseases. Second year fellows will have opportunities to choose an elective rotation. Fellows will be encouraged to identify areas of interest and seize opportunities to engage in impactful, longitudinal projects in various departments.

FOCUSED DEVELOPMENT • Communication and

• Collaborating

Interpersonal Skills

for Solutions

• Medical and

• Project Management

Scientific Expertise

and Prioritization

• Strategic Thinking

• Driving for Results

Global Medical Communications continues to play a critical role in raising awareness of the challenges of living with a rare disease.” CHRISTOPHE HOTERMANS

GLOBAL MEDICAL COMMUNICATIONS– GLOBAL MEDICAL AFFAIRS FELLOWSHIP TEAM DIANE LAWSON, PharmD, RPh FELLOWSHIP PROGRAM DIRECTOR; GMC-GMA PROGRAM LEAD

DEAR PROSPECTIVE FELLOW, Thank you for your interest in the Alexion Fellowship Program in collaboration with Massachusetts College of Pharmacy and Health Sciences (MCPHS) University. As we pursue our mission of transforming lives through the development of innovative therapies for patients with rare diseases in neurology, hematology, and other therapeutic areas—the Global Medical Affairs team, including Global

Diane Lawson is the Senior Director and Head of the Neurology Medical Information-Medical Review team, partnering with US and Global functions. Diane’s 20-year pharmaceutical experience has consisted of various leadership positions managing medical publications, medical information, and R&D programs designed to advance biopharmaceutical careers for physicians and pharmacists new to industry. Prior to joining Alexion in 2018, Diane received her Bachelor of Science in Pharmacy at the University of Iowa, and her Doctor of Pharmacy from the University of Florida.

Medical Communications, continues to play a critical role in serving these patients and raising

AHSAN JAMIL, PharmD

awareness of the challenges of living with a

GMC-GMA PRECEPTOR

rare disease. I wish you the best of luck as you explore the available opportunities and encourage you to consider the Alexion Fellowship Programs. Sincerely, CHRISTOPHE HOTERMANS, MD, PhD SENIOR VICE PRESIDENT, HEAD OF GLOBAL MEDICAL AFFAIRS,

Ahsan Jamil is the Senior Director and Head of Hematology, Nephrology, Transplant within the Global Medical Information-Medical Review team. Ahsan has experience across various medical affairs roles and companies within the pharmaceutical industry. Prior to joining Alexion, his experience spanned several therapeutic areas including oncology, hematology, cardiovascular, metabolics, biosimilars and general medicines. Ahsan received his Doctor of Pharmacy from Rutgers University.

ALEXION, ASTRAZENECA RARE DISEASE

ROTATION 1 OBJECTIVES

ROTATION 2 OBJECTIVES

• DEVELOP and deliver high-quality, balanced and

• DEVELOP strategic partnerships with stakeholders

GLOBAL MEDICAL INFORMATION

GLOBAL MEDICAL REVIEW

timely written or verbal medical and scientific

from Medical Affairs, Clinical Development, Regulatory

information in response to requests from health care

Affairs, Legal, Marketing, Compliance and others to

professionals and consumers

support the development and approval of robust, compelling and accurate materials for healthcare

• CONTRIBUTE to the development and maintenance

providers, patients and other groups

of medical information written responses to address a vast array of inquiries to aid HCPs in

• PROVIDE comprehensive medical review and

consultative expertise for product launch campaigns,

clinical decision-making

congress symposia, speaker decks and other

• SUPPORT Medical Information booth activities prior

materials used by field Medical Affairs and

to, during and after professional scientific meetings

Commercial colleagues

and medical congresses • PARTNER with cross-functional teams (e.g., Medical

• COLLABORATE with subject matter experts

across Medical Affairs and Clinical Development to

Affairs, Marketing, Clinical Development, Competitive

ensure the content of promotional and medical

Intelligence, Pharmacovigilance, Biostatistics, Medical

materials is scientifically appropriate, clinically relevant

Training, Corporate Communications) to contribute to

and aligned to company strategy

product launch activities, development of competitive readiness resources and creation of medical

• PARTICIPATE in live meetings of Promotional and

information deliverables aligning with medical

Medical Review Committees, which are composed

strategic initiatives

of a collaborative, cross-functional team, including Medical, Legal and Regulatory review colleagues and Commercial or Medical content creators

The fellowship’s unique rotational structure encourages innovation and cross-functional collaboration, allowing me to grow professionally and develop new skills while contributing meaningfully to patient care.” SAMANTHA GORSKI, PharmD

ELECTIVE ROTATION OFFERINGS

Fellows will have the opportunity to choose an elective rotation. Rotational areas may include: • Medical

Science Liaison

• Health Economics and

Outcomes Research

• Marketing

• Global Patient Safety

• Regulatory Affairs

• Scientific

• Clinical Development

Communications

GLOBAL MEDICAL COMMUNICATIONS–GLOBAL MEDICAL AFFAIRS FELLOWSHIP TEAM

ZAHRA ARSALAN, PharmD, RPh

MARWA EL-MOUWFI, PharmD

SECOND-YEAR GMC-GMA FELLOW

FIRST-YEAR GMC-GMA FELLOW

As a second-year Global Medical Communications–Global Medical Affairs fellow at Alexion, I’ve continued to grow in a dynamic and mission-driven environment. Through strong mentorship, cross-functional collaboration, and the inspiring experience of contributing to a mission that improves the lives of patients with rare diseases, this fellowship has been truly career-shaping.”

Even in my short time at Alexion, it’s been clear that this fellowship is rooted in genuine support, collaboration, and purpose. The team’s commitment to mentorship and innovation is evident in every interaction, and I’m excited to continue growing through meaningful work in medical information and medical review—contributing to a mission that truly puts patients with rare diseases first.”

SATYAHARSHINI REDDY, PharmD

SAMANTHA GORSKI, PharmD

SECOND-YEAR GMC-GMA FELLOW

FIRST-YEAR GMC-GMA FELLOW

At Alexion, collaboration and innovation are at the forefront of everything we do. This dynamic environment not only fosters professional growth but also offers valuable opportunities to make a meaningful impact on patients living with rare diseases. Being part of this team has provided me with an invaluable environment where I have been able to leverage my skills and learn from a truly forwardthinking group.”

At Alexion, I am honored to help transform the lives of patients with rare diseases as part of the GMC-GMA team. The fellowship’s unique rotational structure encourages innovation and crossfunctional collaboration, allowing me to grow professionally and develop new skills while contributing meaningfully to patient care.”

NICOLE ALDOVER, PharmD, RPh SECOND-YEAR GMC-GMA FELLOW

The people at Alexion are truly what make this fellowship special. I have and continue to receive an endless amount of support, encouragement, and guidance since day one. Alexion has built a team who is passionate about the growth of each individual fellow and dedicated to our successes. Over the next year, I am looking forward to continuing my development at Alexion!”

GLOBAL PATIENT SAFETY 2-YEAR PROGRAM ONBOARDING ~ 6 WEEKS SAFETY SCIENTIST ROTATION 1: POSTMARKETING DRUG SAFETY ~5 MONTHS

SAFETY SCIENTIST ROTATION 2: CLINICAL DEVELOPMENT DRUG SAFETY ~5 MONTHS

ELECTIVE ROTATION*: ~1-3 MONTHS

RETURN TO SAFETY SCIENTIST ROTATION ~8 MONTHS

* Dependent upon interest and availability, the fellow may elect to rotate through additional areas within Safety or other functional areas (eg. Regulatory Affairs, Medical Affairs, Global Medical Communications, Epidemiology, HCP and Patient Marketing)

lobal Patient Safety (GPS)

FOCUSED OBJECTIVES

provides continuous and

• DEVELOP the ability to think strategically and understand the role

proactive assessment, management and

communication of patient risks

of Patient Safety in the lifecycle of products • UNDERSTAND the benefit/risk balance of orphan drugs designed

to treat devastating diseases • CULTIVATE and utilize knowledge in international

associated with Alexion products.

pharmacovigilance regulations and guidelines, to increase

The department aims to optimize

process effectiveness

patient safety while complying with global regulatory requirements, being supported by an agile organization and exemplifying rigorous process management.

• PARTICIPATE and engage in cross-functional team projects

involving Commercial, Marketing, Medical Affairs and Regulatory Affairs to disseminate Global Patient Safety messages • UTILIZE scientific knowledge and research skills to support safety

surveillance and risk management decisions • DEVELOP skills to communicate complex safety messages cross-

functionally and influence decision making KEY ASPECTS OF THE PROGRAM • This two-year program in the Global Patient Safety department

at Alexion is designed to equip the fellow with the proper skill set to progress and have a successful career in the pharmaceutical industry • The program consists of core experiences within Global Patient

Safety and features the opportunity for the fellow to complete an elective rotation, within a separate functional area, depending on the interest of the fellow • The program affords the fellow the unique opportunity to work

on products that treat ultra-rare disease states with no other treatment options 14

Our collaborative approach in Global Patient

GLOBAL PATIENT SAFETY FELLOWSHIP TEAM

Safety ensures the well-being of patients at

CYNTHIA CARRILLO-INFANTE, MD, PhD

every stage of their journey” BOBBY GJORSESKI

EACH YEAR, Alexion, AstraZeneca Rare Disease, offers a distinguished fellowship program designed to train the next generation of patient safety and pharmacovigilance professionals. This program is dedicated to preparing a fellow to contribute meaningfully to the development of

GLOBAL PATIENT SAFETY PROGRAM LEAD

Cynthia Carrillo-Infante is a Physician Scientist with over 15 years of industry experience in Pharmacovigilance overseeing safety of products throughout their lifecycle. Her expertise includes safety of small molecules and monoclonal antibodies in a broad range of therapeutic areas (neurology, immunology, infectious diseases, hematology). Cynthia joined Alexion in 2016 and currently serves as Executive Medical Director in Global Patient Safety within the complement therapeutic area. Prior to joining Alexion, Cynthia worked at Biogen and Vertex Pharmaceuticals where she served as the safety physician lead for several products in development and on the market. Cynthia received her MD from the Panamerican University in Mexico City, Mexico and her PhD in molecular pathology from the University of Siena, Italy.

innovative rare disease therapies that have the potential to transform lives across the globe.

MICHAEL MCDERMOTT, PharmD, RPh

I am delighted to welcome a new fellow, who shares

Michael is a Senior Manager, Safety Scientist in the Global Patient Safety Team at Alexion. In his role, he is responsible for actively monitoring and evaluating the safety of both clinical and marketed products to ensure a positive benefitrisk balance for patients. Michael began his career at Alexion as a Global Patient Safety Fellow and completed the two-year fellowship program in 2023. Michael received his Doctor of Pharmacy from the University of Pittsburgh School of Pharmacy and his Graduate Certificate in Regulatory Affairs from Massachusetts College of Pharmacy and Health Sciences.

our unwavering commitment to putting patients first. Through this fellowship, a pharmacist will have the opportunity to gain hands-on experience in patient safety across all our therapeutic areas and throughout the lifecycle of Alexion’s products. The fellow will collaborate with diverse cross-functional teams, including clinical development, medical affairs, quality and regulatory affairs. This experience provides a comprehensive understanding of the critical role patient safety plays in biopharmaceutical development.

GLOBAL PATIENT SAFETY PROGRAM LEAD

BOBBY GJORSESKI, PharmD, RPh

We seek colleagues who are passionate about alleviating

SECOND-YEAR GLOBAL PATIENT SAFETY FELLOW

the challenges faced by those living with rare and

The emphasis Alexion places on patient safety, the supportive team environment and the abundant opportunities for professional growth as an emerging safety scientist are what make this fellowship so exceptional. Now, more than halfway through my experience, I’ve had the chance to work within the Global Patient Safety team across both the preclinical and post-marketing stages, ensuring patient safety throughout the entire drug development lifecycle. It’s truly rewarding to serve patients living with rare and underserved diseases, and I’m excited to see how I can continue making an impact.”

underserved diseases, and who are motivated to ensure that every patient’s well-being is upheld throughout the entire drug development process. At Alexion, Global Patient Safety is dedicated to enhancing the lives of individuals with rare diseases by rigorously analyzing, understanding and managing the benefit-risk profiles associated with our life-changing therapies. ARSHAD MUJEEBUDDIN, MD VICE PRESIDENT OF PATIENT SAFETY ALEXION, ASTRAZENECA RARE DISEASE

SHREYA PATEL, PharmD FIRST-YEAR GLOBAL PATIENT SAFETY FELLOW

I was drawn to Alexion’s GPS fellowship by the opportunity to develop my career in the rare disease space. Although I entered without a background in patient safety, the supportive and welcoming environment at Alexion made my transition remarkably smooth. The collaboration and kindness of my colleagues have truly set this experience apart. I am eager to further expand my expertise, excel as a safety scientist and contribute meaningfully to improving the lives of patients with rare diseases.” 15

GLOBAL REGULATORY AFFAIRS 2-YEAR PROGRAM GLOBAL REGULATORY AFFAIRS OPPORTUNITIES • Product Strategy

• Chemistry, Manufacturing, and Controls (CMC)

• Regulatory Labeling

lobal regulatory Affairs (GRA), a function within Alexion’s Development, Regulatory and Safety organization, is

responsible for the design and execution of innovative regulatory strategies that drive the advancement and approval of their products to serve patients.

• Regulatory Intelligence

• Regulatory Operations

FOCUSED OBJECTIVES

YEAR 1 • ASSIST with the planning, development, review,

approval and updating of various documents critical to the success of Regulatory initiatives • SUPPORT the Regulatory leads with their

contributions to Regulatory projects and provide helpful insight and guidance • OBSERVE how to develop and execute regulatory

strategy and work successfully with cross-functional teams and US and global health authorities

Through partnership with external stakeholders, GRA colleagues make a positive contribution to the global regulatory environment and provide ongoing support of products that span the development cycle, with

• GAIN a solid understanding of the current Regulatory

landscape, including relevant guidances, enforcement actions, laws, rules and/or regulations

the highest degree of regulatory compliance.

FOCUSED OBJECTIVES

The Alexion GRA fellowship is designed to provide

YEAR 2

the fellow with hands-on exposure to a multitude

• REPRESENT Regulatory as an integral member at

of functions or specialties within GRA and across

cross-functional meetings by providing regulatory

products in Alexion’s therapeutic areas of focus. The

insight, owning action items and contributing

fellow will have the opportunity to build a broad,

feedback and guidance on various documents

robust foundation as a regulatory professional while

and projects

directly contributing to the development of Alexion’s products and the patients they serve. Throughout the program, the fellow will have the ability to tailor the program to their unique interests and overall professional development needs. The fellow will be assigned to the project teams and will work with designated GRA preceptors throughout their rotations in various sub-functions within regulatory.

• LEAD cross-functional teams through

appropriate processes to comply with Regulatory driven commitments • SUPPORT (and potentially drive) the planning,

preparation and submission of regulatory initiatives • SERVE as coordinator for US and global health

authority interactions

Regulatory affairs is a key strategic partner to health

GLOBAL REGULATORY AFFAIRS FELLOWSHIP TEAM

authorities and various functional teams within the

ERICA LEE, RAC

company. We work across the drug development spectrum from research to post-marketing setting, ensuring that what we do every day brings life-changing therapies to patients.” SARAH RHEE

GLOBAL REGULATORY AFFAIRS PRECEPTOR AND PROGRAM LEAD

Erica is a Group Director in the Global Regulatory Affairs, Regulatory Science & Execution group at Alexion. Her role includes leading a team managing end-to-end execution of Regulatory strategies and leading program teams. She has more than 15 years of pharmaceutical experience in roles related to assay development and Regulatory strategy. Prior to Alexion, Erica worked at Shire Pharmaceuticals and Syntimmune, Inc. leading CMC strategy for rare diseases. Erica received her Bachelor of Arts in Biology and Chemistry at Clark University and holds a Regulatory Affairs Certification for Drugs through the Regulatory Affairs Professional Society. MICHELLE TAYLOR, MS GLOBAL REGULATORY AFFAIRS PRECEPTOR

THE GLOBAL REGULATORY AFFAIRS (GRA) fellowship has recruited and retained Pharmacy trainees across different regions for more than a decade and this fellowship program is an important step towards bringing in talented fellows to learn and acquire experience in the regulatory profession. In GRA, we help Alexion shape the drug development story, translating our impactful science into innovative regulatory strategies to gain approval for treatments for patients with high unmet medical need, with the highest quality standards. We champion diversity and inclusion in our teams, which are so important to foster innovation and develop new solutions for patients. We work across the drug development spectrum, ensuring that what we do every day will contribute to developing

Michelle Taylor is a Senior Manager in the Global Regulatory Affairs, Labeling group at Alexion. She supports the CCDS compliance activities and the Global Labeling Business Process. She has 7 years of regulatory experience and has 6 years of Clinical Research experience. Prior to joining Alexion, Michelle worked at Shire Pharmaceuticals and Brigham and Women’s Hospital on the TIMI Study Group. Michelle received her Bachelor’s Degree in Marketing from UMASS Boston and her Master’s in Clinical Research at Emmanuel College. AMBER CONKLIN, PharmD SECOND-YEAR GLOBAL REGULATORY AFFAIRS FELLOW

The GRA Fellowship at Alexion provides a comprehensive, immersive experience across diverse areas of Regulatory Affairs, enhanced by mentorship and top-tier training. Alexion’s collaborative culture and unique rotational program empower fellows to build deep regulatory expertise and meaningful connections, all while contributing to the vital mission of delivering innovative medicines to people living with rare diseases.”

life changing therapies and improve the lives of

ELIUD CARBO ONTIVEROS, PharmD

patients and their families – all by a team of just over

FIRST-YEAR GLOBAL REGULATORY AFFAIRS FELLOW

200 people spread across 18 countries.

The GRA Fellowship at Alexion stands out for its robust rotational structure, exceptional mentorship and strong emphasis on professional growth. From day one, I’ve been supported by a passionate team deeply committed to both transforming patients’ lives and investing in the development of fellows. Through exposure to diverse Regulatory Affairs sub-functions, global collaboration and high-quality training, I’m building the experience and skills needed to become a well-rounded regulatory professional and contribute meaningfully to improving the lives of people affected by rare diseases.”

We are keen on inspiring and being inspired by Pharmacy Fellows who will help us achieve these goals! If you love learning and developing yourself through teamwork, if you are passionate about life sciences and the impact R&D can bring to patients suffering from rare diseases, this fellowship program is a unique opportunity for you! SARAH RHEE, MS VICE PRESIDENT, HEAD OF ALEXION REGULATORY AFFAIRS

GLOBAL VALUE, ACCESS & PRICING 2-YEAR PROGRAM GLOBAL VALUE, ACCESS & PRICING (GVAP) OPPORTUNITIES • Value Proposition Development

•P ricing and Reimbursement Strategy

• Global Healthcare & HTA Insights

• Target Product Profile Creation

lexion’s GVAP team is seeking a

FOCUSED OBJECTIVES

fellow to join a dynamic team.

• SUPPORT development of differentiated target

This strategic role leverages your understanding and application of global healthcare,

Health Technology Assessment (HTA) system knowledge, competitive insights and clinical background to shape market access, pricing and reimbursement success for critical product launches and indications.

product profile that fulfills cross stakeholder needs aligned to robust value proposition • DEVELOP global pricing and reimbursement (P&R)

strategies and framework in close collaboration with launch and program teams • CREATE and roll out value and access communication

tools and materials to support local P&R submissions and negotiations • CULTIVATE understanding of global health care, HTA

systems and latest developing trends especially within rare disease

This fellowship provides an opportunity to develop expertise in the core function of GVAP, with enhanced learning through project work and mentorship within Health Economics and Outcomes Research (HEOR), gaining experience at the intersection of both disciplines. As a fellow, you will learn to lead the development and execution of value, access and pricing strategies for launch assets to support patient access to our medicines. As key parts of the development team, we help shape the clinical development program, develop value propositions that help inform evidence generation activities and establish pricing recommendations for products in our portfolio. While the fellowship is anchored within GVAP, the program is enriched by cross-functional collaboration, including projects and learning experiences in HEOR. The program structure includes further rotational opportunities in areas such as US Market Access, Early Pipeline and Business Development, allowing fellows to customize their journey in line with their interests and organizational priorities. 18

• BUILD a comprehensive understanding of what

evidence payers value across market/payer archetypes • INFLUENCE trial design, outcomes and endpoint

strategy to support payer needs • GAIN exposure to different methodologies to quantify

and fill evidence gaps including burden of disease and unmet need

Join a highly driven team. We are committed to providing sustainable access to breakthrough innovative rare diseases therapies. Our work transforms the lives of patients and their families impacted by rare, debilitating diseases.” PIERRICK ROLLET

GLOBAL VALUE, ACCESS & PRICING AND HEOR FELLOWSHIP TEAM JENNIFER POCOSKI, PharmD GLOBAL VALUE, ACCESS & PRICING PROGRAM DIRECTOR

Jennifer is currently the Global Value, Access & Pricing Head for the metabolic portfolio. Jennifer has held several positions within access and health economics over the last 18 years. She completed her two-year fellowship at Bayer Pharmaceuticals in Medical Affairs and Health Economics. She received her PharmD from Northeastern University. KRYSTAL HUEY, PharmD, MS GLOBAL VALUE, ACCESS & PRICING PROGRAM PRECEPTOR

WE ARE THRILLED that the Global Value, Access & Pricing (GVAP) team will continue this fellowship program in collaboration with MCPHS. We are committed to mentoring new talent within our organization and this accelerated development program will offer a hands-on opportunity to gain a skillset needed to become a future market access leader. PIERRICK ROLLET VICE PRESIDENT OF GLOBAL VALUE, ACCESS & PRICING EXECUTIVE SPONSOR, ALEXION, ASTRAZENECA RARE DISEASE

Krystal is the amyloidosis franchise lead for the metabolics programs. She completed her two-year fellowship at Celgene/BMS in HEOR and GVAP. She received her PharmD from Northeastern University and her MS in Health Outcomes, Policy and Economics from Rutgers University. SIMU THOMAS, M Pharm, MS, PhD GLOBAL HEOR SPONSOR

Simu is the VP and Global Head of HEOR, Medical Communications and Training at Alexion Pharmaceuticals. He has authored more than 35 manuscripts and 75 congress presentations and co-authored book chapters in the field of Health Economics. Simu holds a PhD in Pharmaceutical Economics from the University of Maryland and MS in Pharmacy Administration from the University of Toledo and Pharmacy degrees from Birla Institute of Technology and Science. Simu also serves as Adjunct Assistant Professor at the University of Maryland and Rutgers, The State University of New Jersey. CRAIG WAKEFORD, BA, MA GLOBAL HEOR MENTOR

Craig is currently the Senior Director of HEOR at Alexion. He holds a BA in Economics from the University of Toronto and a Masters in Economics from the University of Ottawa. He has held multiple positions within HEOR and Access in the past 10 years across multiple therapeutic areas. COURTNEY SMITH, PharmD, RPh

SOPHIA SERAFIMOV, PharmD

SECOND-YEAR GVAP FELLOW

FIRST-YEAR GVAP FELLOW

The Global Value, Access, and Pricing fellowship at Alexion is unique in offering exposure to complementary fields, including projects in HEOR and the flexibility to rotate into other areas. I have enjoyed learning f rom an experienced team, tackling complex challenges and ensuring sustainable patient access to rare disease medications.”

I am genuinely excited to learn from the talented and mission-driven GVAP team at Alexion while gaining hands-on experience in the strategic work that supports access to rare disease therapies. I look forward to contributing to evidence generation and value communication efforts that inform global reimbursement and access decisions for patients with limited treatment options.”

PRODUCT DEVELOPMENT AND CLINICAL SUPPLY 2-YEAR PROGRAM CLINICAL SUPPLY AND PHARMACY MANUAL TEAM

EXTERNAL MANUFACTURING & FORECASTING 6 MONTHS

RANDOMIZATION & TRIAL SUPPLY MANAGEMENT 3 MONTHS

INJECTABLES & DRUG PRODUCT DEVELOPMENT 3 MONTHS

GLOBAL CLINICAL SUPPLY MANAGEMENT 12 MONTHS

he Product Development & Clinical Supply (PDCS) fellowship is designed to equip fellows with core skills and expertise to become effective clinical supply managers through applied, hands-on experience. Throughout the program, fellows will build their clinical supply expertise and contribute to advancing Alexion’s mission and values.

CORE ROTATION DESCRIPTIONS

GLOBAL CLINICAL SUPPLY MANAGEMENT

INJECTABLES & DRUG PRODUCT DEVELOPMENT (IDPD)

RANDOMIZATION & TRIAL SUPPLY MANAGEMENT (RTSM)

• Ensure on time delivery of

• Collaborate across functions to

• Support cross functional, global study

Investigational Medicinal Product (IMP) to support clinical trials and patients by overseeing contract manufacturing, packaging, labeling and international distribution. • Collaborate with Clinical

Operations, Quality Assurance (QA), Regulatory Affairs and other cross-functional teams, ensuring proper compliance, efficiency and quality of Alexion clinical trial supplies. • Author and manage pharmacy

manuals to facilitate clinical trial conduct by providing appropriate IMP handling instructions and addressing IMP queries from clinical sites. • Provide accurate supply forecasts

based on study protocol and clinical development plans to guarantee adequate clinical supply and maximize cost efficiency. 20

research, design and execute scientific studies, facilitating the development, characterization and commercial validation of parenteral/ injectable biologic drug products. • Manage the development of various

manufacturing unit operations, including but not limited to, drug substance (DS) freeze/thaw, compounding/mixing, sterile filtration, drug product filling of vials/syringes, visual inspection and DS/DP transportation. • Implement continuous

improvement systems based on lessons learned, enhancing manufacturing technology transfer activities. • Provide support for clinical and

commercial manufacturing sites, including participation in regularly scheduled support meetings, ownership of action items and on-site support as needed.

teams in the end-to-end set-up, delivery, maintenance and archival of RTSM systems as the RTSM subject matter expert. • Coordinate with and manage

the RTSM vendor on delivering RTSM systems in adherence to study timelines, RTSM standards and in accordance to regulatory requirements and guidelines. • Ensure user acceptance testing (UAT)

is performed as needed including authoring UAT plans, coordinating with the RTSM vendor on delivery and support and supporting the study team on UAT.

By joining Alexion, you will become part of a larger team and community, one steeped in patient-centered care and cutting-edge science.” MARK SWIFT

AT ALEXION ASTRAZENECA RARE DISEASE, we are committed to building a world-class organization and our people are our greatest asset for creating those opportunities of growth, learning and collaboration. Our partnership with MCPHS and its fellowship program is an exciting opportunity because it accelerates that impact and allows fellows to learn firsthand through supporting Alexion’s clinical studies. The mentorship and support that fellows will receive through this partnership is unparalleled and will showcase our great talent and commitment to individual learning and growth. The Product Development and Clinical Supply team is committed to supporting Alexion’s clinical studies with the highest level of service and treatment for our patients. Clinical Supply for rare disease indications present nuanced challenges that pave the way for innovative thinking. By joining Alexion, you will become part of a larger team and community, one steeped in patient-centered care and cutting-edge science. MARK SWIFT, JD, BS EXECUTIVE DIRECTOR & HEAD, CLINICAL SUPPLY AND EXTERNAL MANUFACTURING ALEXION, ASTRAZENECA RARE DISEASE

PRODUCT DEVELOPMENT AND CLINICAL SUPPLY FELLOWSHIP TEAM JENNIFER MAHON, PharmD, MS, BS PRODUCT DEVELOPMENT AND CLINICAL SUPPLY PROGRAM LEAD

Jenn is a Director in Global Clinical Supply Management, in addition to being the Pharmacy Manual Team Lead and PDCS Fellowship Director. Jenn has 20 years of experience within R&D and clinical trials, working at Pfizer, Cardinal Health, BMS and Thermo Fisher before joining Alexion. While at Alexion, Jenn was the Clinical Supply Inspection Lead for Voydeya’s approval in USA, EU and Japan.

CRYSTAL MA, PharmD GLOBAL CLINICAL SUPPLY MANAGEMENT LEAD PRECEPTOR

Crystal is an Associate Director in Global Clinical Supply Management at Alexion. Currently, she is the lead clinical supply manager for multiple programs in both early and late phase development. With over 8 years of industry experience, she has developed and managed end-to-end clinical supply chain across various modalities from biologics, small molecules, to CGx. In addition, she also participates in processimprovement workstreams to streamline business workflows within clinical supply management. Crystal received her PharmD from Purdue University and joined Alexion in 2021 after completing a two-year fellowship in Global Clinical Supply with Pfizer/MCPHS.

KATIRIA FLORES, PhD, MS, BS INJECTABLES & DRUG PRODUCT DEVELOPMENT PRECEPTOR

Katiria is a Senior Scientist in the Injectables & Drug Product Development Group. Katiria has 7 years of experience leading the clinical in-use compatibility studies. Her work has supported intravenous and subcutaneous drug product administration for 12 Alexion products in different cycles/phases. Katiria received her BS in Industrial Microbiology from the University of Puerto Rico and her MS and PhD in Physiology and Neurobiology from the University of Connecticut.

AISHA KHOKHAR, PharmD, MHS

HASSAN SLEIMAN, PharmD

SECOND-YEAR PRODUCT DEVELOPMENT AND CLINICAL SUPPLY FELLOW

FIRST-YEAR PRODUCT DEVELOPMENT AND CLINICAL SUPPLY FELLOW

Now in my second year at Alexion, I am excited to continue my journey as the inaugural PDCS fellow. Over the past year, I have gained invaluable insights and experiences that have significantly furthered my career and development in clinical supply management. The rotational aspect of my first year provided a fantastic opportunity to understand the collaboration and teamwork required to bring Alexion’s purpose to life. I am incredibly grateful to work with such wonderful people and to witness firsthand the dedication Alexion has to its patients.”

I’m excited and grateful to start my fellowship at Alexion with the PDCS team and contribute to work that directly impacts patients with rare diseases. The team has been incredibly welcoming and supportive, creating a mission-driven environment full of opportunities to learn, grow and make a difference. I look forward to building my expertise in clinical supply strategy while utilizing my pharmacy training to help deliver life-changing therapies to underserved patient populations.” 21

US MARKET ACCESS 2-YEAR PROGRAM ACCESS STRATEGY & MARKETING 12 MONTHS

STRATEGIC CONTRACTING & PRICING 6 MONTHS

ELECTIVE WITHIN COMMERCIAL ORGANIZATION 6 MONTHS

e are excited to introduce the inaugural Alexion US Market Access Fellowship Program. This unique rotational program allows fellows to actively contribute to the development and execution of Payer Marketing, Contracting and Pricing, and Market Access strategies for Alexion’s diverse and innovative rare

disease portfolio across our franchises. CORE ROTATION OFFERINGS

ACCESS STRATEGY AND MARKETING

STRATEGIC CONTRACTING AND PRICING

• Assist with the development of a payer value

• Gain experience in building and delivering

proposition that effectively communicates clinical and economic benefits to support access strategy. • Collaborate with HEOR, the Payer Account team,

Brand Marketing and Medical Affairs to align on actionable pricing, channel, and payer strategies. • Support tactical planning for a key therapeutic

area, integrating payer and provider initiatives to optimize access. • Collaborate with Field Reimbursement Managers

to ideate, develop and deploy access and reimbursement materials.

ELECTIVE ROTATION OFFERINGS

The fellow will have the opportunity to extend one or more of the core rotations, or select an elective, 6-month rotation either within US Market Access or another functional area within the US commercial organization. Rotational areas may include but are not limited to: • US Trade/Distribution

and Channel Strategy • Strategic Initiatives

and Operations • Contract Management 22

• Payer Customer

Marketing • Brand Marketing • Global Value, Access,

and Pricing

value-based drug pricing recommendations for both medical and pharmacy benefit products. • Support in driving the estimation of potential

return on investment for prospective contracts. • Gain experience in modeling contract scenarios

pre-deal to inform contracting decisions and forecasts. • Coordinate with the Payer Account team to

gather inputs and customer intelligence for contract modeling.

Our teams’ purpose is powerful; we only

US MARKET ACCESS FELLOWSHIP TEAM

exist to better the lives of patients and

RICHARD ANDERSON, BA

their families. We work to ensure that patients have access to our medicines whether insured, underinsured, or uninsured, as innovations only matter if they are accessible to patients.”

HEAD OF US STRATEGIC CONTRACTING PRICING, PROGRAM LEAD

Rick currently leads the US Contracting and Pricing Strategy team at Alexion. He has more than 20 years of experience in US Market Access. Rick earned his BA in Political Science and Government from Brigham Young University. BETH GOULET, BA, MBA SENIOR DIRECTOR, US ACCESS STRATEGY AND MARKETING

EDWARD FEELEY

ABOUT THE FELLOWSHIP

The Alexion/AstraZeneca Rare Disease US Market Access team leads and executes strategies to ensure optimized patient access to our therapies across the portfolio of medications available in the US. By balancing the needs of patients, payers and healthcare systems, the team helps deliver treatments that are both accessible and sustainably priced. Fellows are fully embedded in project teams and contribute

Beth is the US Access Strategy Lead for the Metabolics business unit at Alexion. She has more than 20 years of experience in the industry. Beth earned her BA in philosophy from Harvard University and an MBA from the Wharton School at the University of Pennsylvania. BEN CARROLL, PharmD SENIOR DIRECTOR, US ACCESS STRATEGY AND MARKETING

Ben leads US Access Strategy for the Neurology business unit. He has over 15 years of experience in HEOR, Global and US Market Access. Ben earned his PharmD from the University of Rhode Island.

directly to solving real-world access challenges that impact rare disease patients. The US Market Access Fellowship rotational structure includes core experiences in Access Strategy and Payer Marketing, Strategic Contracting and Pricing, as well as elective opportunities across the broader US commercial organization. By joining this program, fellows position themselves at the forefront of Market

ALEXANDRA BURGER, PharmD, MPH ASSOCIATE DIRECTOR, US PAYER CUSTOMER MARKETING

Alexandra leads the Payer Customer Marketing program for the US Market Access team. She completed her own two-year fellowship at Alexion/AZ and holds a PharmD from Northeastern University and a MPH from MCPHS.

Access in rare disease, helping ensure that patients

SAIRA JATOI, PharmD

have timely access to life-changing therapies.

SENIOR MANAGER, US ACCESS MARKETING

EDWARD FEELEY VICE PRESIDENT, US MARKET ACCESS

Saira is currently a Payer Marketer for the US Market Access team. She completed her fellowship at Alexion/AZ and graduated with a PharmD from the University of Illinois at Chicago.

US MEDICAL AFFAIRS 2-YEAR PROGRAM US MEDICAL AFFAIRS US MEDICAL EXCELLENCE 6 MONTHS

US MEDICAL DIRECTOR 6 MONTHS

US MEDICAL SCIENCE LIAISON 6 MONTHS

ELECTIVE 6 MONTHS

S Medical Affairs (USMA) is a rotational program with 6-month rotations in US Medical Excellence, US Medical Director and US Medical Science Liaison positions. The schedule for core rotations will be individualized, to align the fellow with major developments within Alexion. The program also allows for a final 6-month elective

rotation in any area the fellow desires. CORE ROTATION OFFERINGS

US MEDICAL EXCELLENCE

US MEDICAL DIRECTOR

US MEDICAL SCIENCE LIAISON

Under the guidance of the Medical Communications Leads

• Develop leadership skills and

• Participate in Medical Science

• Develop and update scientific

field materials and develop an understanding of the medical review process • Participate in the planning and

execution of USMA activities at national medical congresses • Identify, develop, and execute

trainings to increase scientific knowledge and skill development • Work on special projects

as needed, which further strategic imperatives

fundamental knowledge in the area of strategic planning • Support Medical Directors on

tactical implementation of key program initiatives • Participate in cross-functional

projects to create internal and external deliverables • Contribute to strategic

activities including advisory boards, evidence generation, publication planning and competitive differentiation

Liaison (MSL) onboarding and certification • Provide medical support at

medical congresses via abstract coverage, booth staffing and Key Opinion Leader (KOL) engagement • Actively participate with MSLs

in their field engagements • Observe and learn from

USMA leadership

ELECTIVE ROTATION OFFERINGS

The fellow will have the opportunity to extend one or more of the core rotations, or select an elective, 6-month rotation either within USMA or another functional area. Rotational areas may include but are not limited to: • US Regulatory Advertising

and Compliance

• Global Patient Safety

(Pharmacovigilance)

• Scientific Communications • Health Economics and

• Quality Affairs

• Commercial

• Global Medical Affairs

• US Medical Affairs Pipeline

• Field Systems and Analytics

• Clinical Development

• US Medical Review

• Medical Information

Outcomes Research

By providing unparalleled resources

US MEDICAL AFFAIRS FELLOWSHIP TEAM

and mentorship, we empower fellows to

SUSAN LENHART-HERMAN, PharmD, RPh, BCPS

drive innovation and make meaningful contributions to patient care.” NAEEM KHAN

DEAR PROSPECTIVE FELLOW, We are excited to recruit and mentor new talent within the US Medical Affairs team. This fellowship represents our commitment to advancing medical research and fostering the next generation of leaders in the field. By providing unparalleled resources and mentorship, we empower fellows to drive innovation and make meaningful contributions to patient care. We are looking for passionate individuals to join our team who embody the innovative spirit to break barriers for our patients living with rare diseases. NAEEM KHAN VICE PRESIDENT, US MEDICAL AFFAIRS

US MEDICAL AFFAIRS PROGRAM CO-LEAD

Susan has worked in the pharmaceutical industry for over 20 years gaining a wide range of experiences in field-based medical affairs. In her current role as Associate Director, Medical Communications LeadBone Metabolism and Rare Endocrinology on the US Medical Excellence team, she is committed to supporting the success of the field-based teams via the development of highly scientific and engaging resources aligned with medical affairs strategy. She has always had a passion for teaching and mentoring and is excited to champion the professional growth and development of the fellows.

RADA ZUNICH, PharmD, RPh

US MEDICAL AFFAIRS PROGRAM CO-LEAD

Rada earned her PharmD in 2023 from the University of North Carolina Eshelman School of Pharmacy. She joined Alexion as the inaugural US Medical Affairs fellow through the two-year fellowship program. Following the completion of her fellowship, she transitioned into a full-time position as Senior Manager, Medical Communications Lead for Nephrology. Most recently, Rada has taken on the additional responsibility of co-leading the USMA program.

SAWYER PATRICK, PharmD, RPh SECOND-YEAR US MEDICAL AFFAIRS FELLOW

Upon meeting the team at Alexion, I knew this fellowship was the perfect fit for me. With exposure to ultra-rare diseases and expert mentorship, I was introduced to multiple areas of Medical Affairs in a field that demands constant innovation. Over the past year, I’ve had the opportunity to collaborate on several cross-functional projects and help champion new solutions for our patients.”

SARAH YOUNG, PharmD, MBA

OWEN JUNEJA, PharmD

FIRST-YEAR US MEDICAL AFFAIRS FELLOW

The passion each Alexion employee has for rare diseases and helping patients is truly inspiring. The rotational nature of the fellowship also stood out, offering a comprehensive view of medical affairs and supporting my growth as a well-rounded professional. Most importantly, everyone I spoke with was incredibly welcoming and genuinely interested in getting to know me, reflecting a strong and inclusive company culture.”

When I first met the USMA team, I was immediately struck by how friendly and welcoming their team culture was. I instantly felt comfortable and knew this was the right environment to support my growth as a new graduate. The rotational structure of the program was another key factor in my decision - it offers the unique opportunity to explore multiple areas of medical affairs and find where I best thrive. I am genuinely excited to be a part of a team that will both challenge me to become the best version of myself and equip me with the tools and mentorship to do so.”

US REVIEW AND STRATEGY 2-YEAR PROGRAM US AD PROMO 6 MONTHS

US MARKETING 6 MONTHS

US MEDICAL REVIEW 6 MONTHS

ELECTIVE 6 MONTHS

S Review and Strategy is a rotational program with 6-month rotations in US Advertising and Promotional Compliance (Ad Promo), US Marketing and US Medical Review. The schedule for core rotations will be individualized, to align the fellow with major developments within Alexion. The program also allows for a final 6-month elective

rotation in any area the fellow desires.

CORE ROTATION OFFERINGS

US AD PROMO

US MARKETING

US MEDICAL REVIEW

• Provide strategic, high-quality,

• Develop strategic and critical

• Develop mastery of clinical

timely and decisive advice on advertising and promotional materials, communications, and company activities in accordance with FDA regulations, company policies and business goals • Support the dissemination of

new or updated FDA policies, enforcement actions or guidance documents • Support regulatory leads on

projects and initiatives • Assist and support 2253

submissions to the Office of Prescription Drug Promotion (OPDP)

understanding of clinical data to translate into compelling brand messaging • Develop an understanding of

core marketing fundamentals, commercial operations, agency management and business processes • Leverage key customer and market

insights in the development of initiatives to support and advance the brand priorities • Work cross functionally with

partners in Ad Promo, Medical and Legal to guide marketing materials through the US promotional review process

data and regulations regarding promotion and scientific exchange • Demonstrate subject matter

expertise in both disease state and product(s) by actively participating in promotional review and medical review committee meetings and defending any comments • Support, collaborate and provide

guidance to/with cross-functional partners • Support, attend and provide

guidance for any promotional video shoots

• Develop and foster relationships

with external agency partners for the timely delivery of resources ELECTIVE ROTATION OFFERINGS

• Clinical Development

• Scientific Communications

• Medical Information

• Global Patient Safety

• Health Economics and

• Global Medical Affairs

(Pharmacovigilance)

Outcomes Research

• US Medical Affairs Pipeline

• Field Systems and Analytics

We look forward to supporting the professional growth of the next generation of leaders in medical and regulatory review through this exciting opportunity.” US REVIEW AND STRATEGY FELLOWSHIP TEAM

This initiative reflects our dedication to nurturing emerging talent within our organization and engaging enthusiastic individuals to lead the expansion of our team. This innovative program is designed to offer a comprehensive and immersive experience in navigating the complexities of medical, regulatory and marketing landscapes. Fellows will gain hands-on experience, work closely with industry experts and develop critical skills needed to excel in these pivotal areas. We look forward to supporting the professional growth of the next generation of leaders in medical and regulatory review through this exciting opportunity.

US REVIEW AND STRATEGY FELLOWSHIP TEAM MATTHEW MAULIS, PharmD US REVIEW AND STRATEGY PROGRAM LEAD

Matthew is a Director and currently supports US Medical Review within the hematology & nephrology therapeutic area, serving as the lead hematology medical reviewer. He received his PharmD from Lipscomb University in 2018 and completed a post-doctoral fellowship in Medical Information & Medical Affairs with Sunovion Pharmaceuticals and MCPHS University. After completing his fellowship, he remained at Sunovion, and served as both a preceptor and director of their fellowship program. Matthew enjoys mentoring fellows and assisting them in discovering their path within the industry and ensuring they have all the tools necessary for a successful career within the industry.

MICHELLE BELLIVEAU, MLS, MSRA US AD PROMO PRECEPTOR

Michelle Belliveau works within US Medical Affairs as an Associate Director providing Regulatory Advertising and Promotional Compliance support for marketed and investigational products within the Rare Disease Business Unit, primarily focusing on therapeutic areas within metabolics. Prior to working at Alexion, AstraZeneca Rare Disease, other industry experience included Takeda Pharmaceuticals, supporting the Oncology Business Unit in various roles within Regulatory Affairs, Marketing, and Quality Assurance. Michelle attended Massachusetts College of Pharmacy and Health Sciences obtaining a Masters in Regulatory Affairs and Health Policy, as well as Simmons College, obtaining a Masters in Library and Information Science with a specialization in Archives Management, working within multiple libraries within Boston, MA. ALEXANDRA MARESH, PharmD, RPh US MEDICAL REVIEW PRECEPTOR

Alexandra is an Associate Director and currently serves as the US Medical Review lead for the metabolics therapeutic area. She received her PharmD from the University of Pittsburgh in 2020 and completed a post-doctoral fellowship in Global Medical Information & Medical Affairs in affiliation with Alexion/MCPHS University. After completing her fellowship, she remained at Alexion as a medical reviewer, initially supporting the neurology therapeutic area before returning to the metabolics franchise. Alexandra aims to provide guidance and mentorship to fellows as they navigate their professional journey, hoping to help equip them with the support and resources they need to make the most of every opportunity the program has to offer. NICK AVALLONE, MBA US MARKETING PRECEPTOR

Nick is a Senior Director and currently serves as the US Marketing Lead for the PNH portfolio of therapeutic products. In his role, he directs the development and execution of commercial strategy, oversees brand management and messaging, and advances education for healthcare providers and patient populations. Nick is accountable for portfolio sales performance and for ensuring close alignment among cross-functional teams supporting the PNH portfolio. He brings more than twenty years of experience in US biopharmaceutical marketing, encompassing a broad range of specialties, including rare diseases. Nick holds a BS in Biochemistry from the University of Kansas and a MBA from the UCLA Anderson School of Management. FAYTH MORRIS, PharmD, MPH FIRST-YEAR US REVIEW AND STRATEGY FELLOW

After connecting with the team at Alexion, I knew this fellowship was the perfect fit for me. I was inspired by their passion for rare diseases and patient care. As the program’s inaugural fellow, the team’s warm, welcoming nature has made me feel at home. I’m eager to engage in the unique rotations and invaluable mentorship offered, fostering my growth as a well-rounded industry professional.” 27

PAST FELLOWS

GABRIELA MARCHEVA, PharmD 2017–2019

CALANTHA YAN, PharmD, RPh 2020–2022

PAUL PARK, PharmD 2022-2024

GLOBAL MEDICAL DIRECTOR AT SANOFI

SENIOR SAFETY SCIENTIST AT SEAGEN

SENIOR MANAGER, NORTH AMERICA MEDICAL AT RHYTHM PHARMACEUTICALS

ADAM QUICQUARO, PharmD 2018–2020

CHRISTINE BORUNDA, PharmD, RPh 2020–2022

BRIAN ARANA-MADRIZ, PharmD 2022-2024

DIRECTOR, CLINICAL DEVELOPMENT SCIENTIST AT ALEXION

SENIOR MEDICAL SCIENCE LIAISON AT AMGEN

ASSOCIATE DIRECTOR, REGULATORY AFFAIRS AT ASTRIA THERAPEUTICS

MATTHEW LUEN, PharmD 2018–2020

MICHELLE CIAMBELLA, PharmD, RPh 2020–2022

MAYA OSMAN, PharmD 2022-2024

HCP MARKETING AT AMGEN

DIRECTOR, MEDICAL COMMUNICATIONS & PUBLICATIONS AT IPSEN

MEDICAL SCIENCE LIAISON AT AMGEN

KATIE SWANNER, PharmD 2019–2021

MICHAEL MCDERMOTT, PharmD, RPh 2021–2023

TIM O’NEILL, PharmD, RPh 2022-2024

DIRECTOR, MEDICAL AFFAIRS AT INOZYME PHARMA

SENIOR MANAGER, SAFETY SCIENTIST AT ALEXION

SENIOR MANAGER, US MEDICAL REVIEW AT ALEXION

DIAN LIN, PharmD 2019–2021

ALEXANDRA BURGER, PharmD 2021–2023

THO DAO, PharmD 2023-2025

ASSOCIATE DIRECTOR, VALUE, ACCESS & PRICING AT SPRINGWORKS THERAPEUTICS

ASSOCIATE DIRECTOR, PAYER CUSTOMER MARKETING AT ALEXION

MSL, USMA NEUROLOGY AT ALEXION

ALEXANDRA MARESH, PharmD, RPh 2020–2022

JANKI PATEL, PharmD, RPh 2022-2024

CHRISTINA MILLER, PharmD, RPh 2023-2025

ASSOCIATE DIRECTOR, US MEDICAL REVIEW AT ALEXION

SENIOR MANAGER, SAFETY SCIENCES AND OPERATIONS AT BICARA THERAPEUTICS

SENIOR MANAGER, US MEDICAL REVIEW AT ALEXION (NEUROLOGY)

JULIA SETTLER, PharmD, MBA 2023-2025 SENIOR MANAGER, US MEDICAL REVIEW AT ALEXION

ROSETTA TOLLEY, PharmD, RPh 2023-2025 SENIOR MANAGER, SAFETY SCIENTIST AT ALEXION

MORGAN LOH, PharmD 2023-2025 SENIOR MANAGER, US ADVERTISING AND PROMOTIONAL COMPLIANCE AT ALEXION

SAIRA JATOI, PharmD 2023-2025 SENIOR MANAGER, US ACCESS MARKETING AT ALEXION

RADA ZUNICH, PharmD, RPh 2023-2025 SENIOR MANAGER, US MEDICAL COMMUNICATIONS LEAD AT ALEXION (NEPHROLOGY)

MCPHS

CPHS provides an academic environment to guide and support fellows toward a successful career in the

biopharmaceutical industry. As a private institution with a history of specializing in health sciences, MCPHS offers programs that embody scholarship, professional service and community outreach. Through the affiliation with MCPHS, fellows will have the opportunity to gain teaching and research experience in an academic setting. MCPHS faculty and company program leaders mentor fellows according to their scholarly and professional interests throughout the two-year program.

AS AN ADJUNCT INSTRUCTOR AT MCPHS, FELLOWS WILL HAVE THE OPPORTUNITY TO: • DEVELOP, coordinate and teach courses • CO-PRECEPT pharmacy students on advanced

experiential rotations • CREATE and publish scholarly research and/or

review articles • PRESENT research at scientific and

clinical meetings • PARTICIPATE in professional development

seminars with other MCPHS fellows

The Alexion fellowship provides a unique opportunity to gain practical and valuable hands on experience that will allow for a successful and fruitful career in the biopharmaceutical industry.” MATTHEW LUEN Past Fellow, Global Medical Communications–Global Medical Affairs

MCPHS TEAM AMEE MISTRY, PharmD, RPh

SHEILA SEED, PharmD, MPH, CTH ®, AFTM RCPS(Glasg), RPh

DIRECTOR OF THE POSTDOCTORAL BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM AND MCPHS FACULTY PRECEPTOR

MCPHS FACULTY PRECEPTOR

Dr. Amee Mistry is a Professor of Pharmacy Practice and has been with MCPHS since 2006. Dr. Mistry earned her PharmD at the Albany College of Pharmacy and completed a PGY1 Community Practice Residency with Walgreens and MCPHS. In 2015, Dr. Mistry took over as Director of the MCPHS Biopharmaceutical Industry Fellowship program. She works directly with leaders in the area to continue to foster growth and development of the post graduate program, and to assist the fellows in attaining positions within the pharmaceutical industry. She also continues to teach and conduct scholarly work at MCPHS, trains pharmacists and student pharmacists nationally on immunizations, and is actively involved in her state and national pharmacy organizations. TRISHA LAPOINTE, PharmD, BCPS, FASHP, FMSHP, RPh MCPHS FACULTY PRECEPTOR

Dr. LaPointe is a Professor of Pharmacy Practice at MCPHS. She earned her doctorate in pharmacy from Northeastern University in 2001 and completed her PGY-1 at Massachusetts General Hospital in Boston Massachusetts. Dr. LaPointe’s current practice site at Lowell General Hospital where she sees patients in the inpatient care setting and mentors student pharmacists on inpatients general medicine rotations. Dr. LaPointe works with students, residents, and fellows to carry out scholarly pursuits. EWAN MCNICOL, PharmD, RPh, MS MCPHS FACULTY PRECEPTOR

Dr. McNicol is a Professor of Pharmacy Practice at MCPHS where he maintains a practice site in ambulatory pain management at Atrius Health in Boston. He received his Doctor of Pharmacy degree from MCPHS in Boston in 2016. In addition, he has a Master’s degree in Pain Research, Education and Policy from Tufts University from 2001. He conducts evidence-based reviews of analgesic interventions and outcomes for pain and related conditions, and has collaborated with current and former pharmacy fellows as a preceptor in this research.

Sheila Seed is Professor and Chair for the Department of Pharmacy Practice at the Massachusetts College of Pharmacy and Health Sciences (MCPHS) School of Pharmacy Worcester/Manchester campuses. During the pandemic, she served as the University’s COVID-19 Coordinator for all three campuses. She received her B.S in Pharmacy from the Massachusetts College of Pharmacy and Health Sciences, Boston, Masters of Public Health from the University of Massachusetts, Amherst and Doctor of Pharmacy (Pharm.D.) from Idaho State University. She has been a faculty member at MCPHS since 2001. Prior to her appointment, she worked in the community setting and as a pharmacy officer in the U.S. Air Force. Her areas of interests include public health, immunizations and travel medicine. She has a Certificate of Travel Health™ (CTH)®, and is an Associate Faculty Member of Travel Medicine at the Royal College of Physicians and Surgeons (Glasgow). She has served as the Secretary of Knowledge Management and the Chair of the AACP Public Health SIG and a past Coordinator of the APhA Immunization SIG. She continues to work with the SIG on updating the APhA Travel Health Quick Guide annually. YULIA MURRAY, PharmD, RPh MCPHS FACULTY PRECEPTOR

Dr. Murray received her Doctor of Pharmacy degree from MCPHS University in Worcester, Massachusetts, and completed her Pharmacy Practice Residency at Beth Israel Deaconess Medical Center in Boston. Following her residency, she practiced as a Clinical Medicine Pharmacist at Boston Medical Center before transitioning to a full-time faculty role at MCPHS University. Dr. Murray is currently an Associate Professor of Pharmacy Practice at the MCPHS University School of Pharmacy–Boston. Her clinical practice site is at NewtonWellesley Hospital, where she serves as a clinical pharmacist on the adult internal medicine service and precepts students on both IPPE and APPE rotations. Dr. Murray has a strong interest in interprofessional education and currently serves as Chair of the Interprofessional Education (IPE) Committee for the School of Pharmacy–Boston. She is actively involved in several professional pharmacy organizations and currently serves as a Director for the Massachusetts Society of Health-System Pharmacists. PHUNG C. ON, PharmD, BCPS, RPh MCPHS FACULTY PRECEPTOR

Dr. Phung On is an Associate Professor of Pharmacy Practice at MCPHS. She is the Academic Coordinator on the Boston Campus for the Biopharmaceutical Industry Fellowship program and the Community Engagement Coordinator for the School of Pharmacy – Boston. She earned her Doctor of Pharmacy degree from MCPHS and completed a PGY1 Pharmacy Practice Residency with a focus on ambulatory care, managed care, and transitions of care at the University of North Carolina at Chapel Hill and AccessCare, a network of the Community Care of North Carolina. Dr. On maintains a clinical practice site in ambulatory care at Codman Square Health Center in Boston where she works collaboratively with the primary care team to manage patients’ chronic diseases. 31

APPLICATION REQUIREMENTS ELIGIBILITY

APPLICATION REVIEW AND INTERVIEW TIMELINE

The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.

Following a review of submitted applications, pre-screens and preliminary interviews will begin in October. Additional interviews, including final rounds will take place in December during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore, candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.

• Candidates must have strong written and verbal

communication skills and a strong interest in pursuing a career within the biopharmaceutical industry. • All candidates must have authorization to work in the

United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.). APPLICATION PROCEDURE

The MCPHS application portal (SMApply) will open on Monday October 6, 2025. Applicants must upload the following application materials to the online portal (mcphs.smapply.io) by Monday November 3, 2025:

ASHP MIDYEAR & ONSITE INTERVIEWS

The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Las Vegas, NV. Attendance is strongly encouraged, but not required. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details. Top candidates may be invited for interviews at the sponsoring company’s location.

• Letter of intent (addressed to the company specific

program director/lead; found in each company brochure) • Curriculum vitae • Unofficial college transcript • Contact information for three references. References

will receive an electronic recommendation form to complete separately. Three recommendation evaluation forms must be submitted no later than November 20, 2025 via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMApply.

AIFA FIRST OFFER DATE

The choice of a Postdoctoral Fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for Fellowships no earlier than Friday December 12, 2025. We believe this is a positive reflection of the cultures our Programs offer and that culture is a critical consideration in choice of Fellowship. We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date. ONBOARDING

Final candidates will be required to go through additional screening / onboarding as required by MCPHS. FOR MORE INFORMATION, PLEASE EMAIL:

PharmD.Fellowships@alexion.com

BOSTON CAMPUS 179 Longwood Avenue Boston, MA 02115-5896

Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard Boston, MA 02210 32

MANCHESTER CAMPUS 1260 Elm Street Manchester, NH 03101

WORCESTER CAMPUS 19 Foster Street Worcester, MA 01608-1715